Market Overview

Cowen Analyst Thinks Shire-Radius Health Merger Is Unlikely After Visit With CEO

Cowen Analyst Thinks Shire-Radius Health Merger Is Unlikely After Visit With CEO
Related RDUS
35 Stocks Moving In Monday's Mid-Day Session
Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline
Radius Health (RDUS) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow (Seeking Alpha)
40 Biggest Movers From Yesterday
32 Stocks Moving In Tuesday's Mid-Day Session
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update (Seeking Alpha)
  • Shares of Radius Health Inc (NASDAQ: RDUS) spiked 20.72 percent on massive volume (3.8 million shares, versus the 1.1 million average) on Thursday.
  • The surge seemed to have been triggered by rumors about a possible takeover by Shire PLC (ADR) (NASDAQ: SHPG).
  • Shares of Shire rose 2.77 percent during the regular trading session, but fell almost 2 percent in after-hours Thursday.

Radius Health’s stock spiked on Thursday following rumors that say Shire intends to make a takeover offer of $90 per share for the company. It should be noted that this is a huge premium to Radius’ stock’s current valuation -- shares opened at $54.15 on Thursday.

So far, both Radius and Shire have declined to comment.

To shed some light on the subject, Benzinga contacted research firm Cowen & Co.

A prominent analyst at the firm, Dr. Eric Schmidt, revealed the following in a phone interview:

1. The Shire-Radius rumor seems unlikely. Shire has been subject of plenty of speculation regarding its M&A activity recently.

2. Radius Health’s President and CEO visited Cowen’s office on Thursday afternoon and did not say anything about the potential acquisition.

Radius stock does not yet appear to be reacting to the possibility that the latest rumor is false. Shares breached the $66 level in Thursday's afte-hours session after bottoming at $46.32 just one day earlier.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Image credit: Public Domain

Latest Ratings for RDUS

Feb 2018JP MorganMaintainsOverweight
Jan 2018Morgan StanleyInitiates Coverage OnOverweight
Nov 2017JefferiesMaintainsHold

View More Analyst Ratings for RDUS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Short Ideas Health Care M&A Top Stories Exclusives Analyst Ratings Best of Benzinga


Related Articles (SHPG + RDUS)

View Comments and Join the Discussion!